Bhagya Shree Choudhary
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Bhagya Shree Choudhary has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Nazia Chaudhary
Advanced Centre for Treatment Research and Education in Cancer (ACTREC), Tata Memorial Centre, Kharghar Node 1 Cell and Tumour Biology Navi Mumbai 410210
24 shared publications - Sorab Nariman Dalal
Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre, Navi Mumbai, India
23 shared publications - Nandini Verma
Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Navi Mumbai, Maharashtra, Índia
22 shared publications - Afiya Dalwai
Cell and Tumor Biology, Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre, Navi Mumbai, India
20 shared publications - Akshaya B
Cell and Tumor Biology, Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre, Navi Mumbai, India
20 shared publications - Alessandro La Ferlita
The Ohio State University, Columbus, Ohio, United States
20 shared publications
Latest Publications
- Open Access
- 1 June 2025
- Published by The Company of Biologists in Journal of Cell Science
- Vol. 138 (11)
LCN2 promotes focal adhesion formation and invasion by stimulating c-Src activation
Previous work has demonstrated that lipocalin2 (LCN2) expression promotes invasion and migration in multiple tumor types. The mechanisms by which LCN2 promotes invasion and migration remain unclear. Previous work from our laboratory demonstrated that LCN2 promotes actin filament formation by inhibiting actin glutathionylation. In this study, we demonstrate that, in addition to inhibiting actin glutathionylation, LCN2 stimulates invasion by promoting the formation of focal adhesions, which is independent of the ability of LCN2 to bind iron (Fe3+). We showed that LCN2 promotes focal adhesion formation by promoting the activation of c-Src (also known as SRC) by stimulating expression of the transcription factor ETS1. ETS1, in turn, upregulates expression of the protein phosphatase PTP1B, resulting in the auto-activation of c-Src and increased paxillin phosphorylation, leading to focal adhesion formation. These results demonstrate that LCN2 has iron-dependent and -independent functions in promoting invasion and highlight the multiple mechanisms by which LCN2 promotes invasion, suggesting that c-Src inhibitors could be used to treat invasive colorectal cancer.
- 1 June 2025
- Published by The Company of Biologists in Journal of Cell Science
- Vol. 138 (11)
Open AccessLCN2 promotes focal adhesion formation and invasion by stimulating c-Src activation
Previous work has demonstrated that lipocalin2 (LCN2) expression promotes invasion and migration in multiple tumor types. The mechanisms by which LCN2 promotes invasion and migration remain unclear. Previous work from our laboratory demonstrated that LCN2 promotes actin filament formation by inhibiting actin glutathionylation. In this study, we demonstrate that, in addition to inhibiting actin glutathionylation, LCN2 stimulates invasion by promoting the formation of focal adhesions, which is independent of the ability of LCN2 to bind iron (Fe3+). We showed that LCN2 promotes focal adhesion formation by promoting the activation of c-Src (also known as SRC) by stimulating expression of the transcription factor ETS1. ETS1, in turn, upregulates expression of the protein phosphatase PTP1B, resulting in the auto-activation of c-Src and increased paxillin phosphorylation, leading to focal adhesion formation. These results demonstrate that LCN2 has iron-dependent and -independent functions in promoting invasion and highlight the multiple mechanisms by which LCN2 promotes invasion, suggesting that c-Src inhibitors could be used to treat invasive colorectal cancer.
- Open Access
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S9 from Patient-Derived Organoids and Xenografts Uncover Therapeutic Vulnerabilities in Colorectal Signet Ring Cell Carcinomas
High MUC2 expression is associated with resistance to therapy.
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S9 from Patient-Derived Organoids and Xenografts Uncover Therapeutic Vulnerabilities in Colorectal Signet Ring Cell Carcinomas
High MUC2 expression is associated with resistance to therapy.
- Open Access
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Patient-Derived Organoids and Xenografts Uncover Therapeutic Vulnerabilities in Colorectal Signet Ring Cell Carcinomas
Drug toxicity testing in SRCC PDO models.
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Patient-Derived Organoids and Xenografts Uncover Therapeutic Vulnerabilities in Colorectal Signet Ring Cell Carcinomas
Drug toxicity testing in SRCC PDO models.
- Open Access
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Patient-Derived Organoids and Xenografts Uncover Therapeutic Vulnerabilities in Colorectal Signet Ring Cell Carcinomas
Drug toxicity testing on SRCC PDO models.
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Patient-Derived Organoids and Xenografts Uncover Therapeutic Vulnerabilities in Colorectal Signet Ring Cell Carcinomas
Drug toxicity testing on SRCC PDO models.
- Open Access
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Patient-Derived Organoids and Xenografts Uncover Therapeutic Vulnerabilities in Colorectal Signet Ring Cell Carcinomas
Characterization of mucin-high PDX models over the passage.
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Patient-Derived Organoids and Xenografts Uncover Therapeutic Vulnerabilities in Colorectal Signet Ring Cell Carcinomas
Characterization of mucin-high PDX models over the passage.
- Open Access
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Patient-Derived Organoids and Xenografts Uncover Therapeutic Vulnerabilities in Colorectal Signet Ring Cell Carcinomas
Drug toxicity testing in SRCC PDO models.
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Patient-Derived Organoids and Xenografts Uncover Therapeutic Vulnerabilities in Colorectal Signet Ring Cell Carcinomas
Drug toxicity testing in SRCC PDO models.
- Open Access
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S7 from Patient-Derived Organoids and Xenografts Uncover Therapeutic Vulnerabilities in Colorectal Signet Ring Cell Carcinomas
The genetic characterization of the patient samples
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S7 from Patient-Derived Organoids and Xenografts Uncover Therapeutic Vulnerabilities in Colorectal Signet Ring Cell Carcinomas
The genetic characterization of the patient samples
- Open Access
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Patient-Derived Organoids and Xenografts Uncover Therapeutic Vulnerabilities in Colorectal Signet Ring Cell Carcinomas
Different media compositions used for the culture of SRCC organoids. 8 different culture media with different growth factors and small molecule inhibitors were used for the optimization of SRCC colon and rectal organoids.
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Patient-Derived Organoids and Xenografts Uncover Therapeutic Vulnerabilities in Colorectal Signet Ring Cell Carcinomas
Different media compositions used for the culture of SRCC organoids. 8 different culture media with different growth factors and small molecule inhibitors were used for the optimization of SRCC colon and rectal organoids.
- Open Access
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Patient-Derived Organoids and Xenografts Uncover Therapeutic Vulnerabilities in Colorectal Signet Ring Cell Carcinomas
Catalog number, company name, and dilutions of antibodies used for Western blotting and immunofluorescence.
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Patient-Derived Organoids and Xenografts Uncover Therapeutic Vulnerabilities in Colorectal Signet Ring Cell Carcinomas
Catalog number, company name, and dilutions of antibodies used for Western blotting and immunofluorescence.
- Open Access
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from Patient-Derived Organoids and Xenografts Uncover Therapeutic Vulnerabilities in Colorectal Signet Ring Cell Carcinomas
Number of passages of the PDX and PDO models generated in this study.
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from Patient-Derived Organoids and Xenografts Uncover Therapeutic Vulnerabilities in Colorectal Signet Ring Cell Carcinomas
Number of passages of the PDX and PDO models generated in this study.